Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25

Core Insights - The company reported a 3% increase in revenue to DKK 27,874 million for FY 2024/25, with an organic growth of 7% and an EBIT margin of 28% [1][8] - The Board of Directors proposed a year-end dividend of DKK 18.00 per share, raising the total dividend for the year to DKK 23.00 per share, compared to DKK 22.00 per share last year [2] Financial Performance - EBIT for FY 2024/25 was DKK 7,670 million, reflecting a 5% increase from the previous year, with an EBIT margin improvement from 27% to 28% [8] - Adjusted net profit before special items was DKK 5,148 million, an increase of DKK 123 million from last year, with adjusted diluted EPS before special items rising by 2% to DKK 22.84 [8] - The adjusted free cash flow-to-sales ratio improved to 19% from 15% last year [8] Business Segments - Organic growth rates by business area were as follows: Ostomy Care 6%, Continence Care 8%, Voice & Respiratory Care 9%, Wound & Tissue Repair 8%, and Interventional Urology 2% [1] Special Items and Expenses - Special items expenses totaled DKK 469 million, related to profitability improvement initiatives, including the Skin Care divestment and management restructuring [2] Sustainability Initiatives - Production waste recycling increased to 83% in FY 2024/25, surpassing the 2025 target of 75% [3] - Scope 1 and 2 emissions decreased by 41% compared to the base year 2018/19, a significant improvement from the previous year's reduction of 22% [4] Future Guidance - For FY 2025/26, the company anticipates around 7% organic revenue growth and EBIT growth in constant currencies, with a return on invested capital expected to be around 16% [5][6] - Reported growth in DKK is projected at 4-5%, with a negative impact from currencies and the skin care divestment [5]